In a report released today, Difei Yang from Mizuho Securities assigned a Buy rating to Viewray (NASDAQ: VRAY), with a price target of $13. The company’s shares closed on Friday at $11.05.
According to TipRanks.com, Yang is a top 100 analyst with an average return of 23.0% and a 54.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viewray with a $13.58 average price target, a 23.0% upside from current levels. In a report issued on July 24, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
Based on Viewray’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $21.99 million. In comparison, last year the company had a GAAP net loss of $8.35 million.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
